Public advisory - Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection
OTTAWA, ON, July 7, 2023 /CNW/ -
Summary
Product: Rhinaris Nasal Mist 30 mL (lot 230391A)
Issue: Health products - Product safety
What to do: Do not use the affected product. Return it to your local pharmacy for proper disposal.
Images
Affected products
Product
DIN
Lot
Expiry date
UPC
Rhinaris Nasal Mist 30 mL
02354551
230391A
31-05-2025
5760622302
Issue
The Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.
Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages in adults and children at least two years of age.
The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.
Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).
While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.
What you should do
Do not use the affected product. Return it to your local pharmacy for proper disposal.
Consult a health care professional if you have used this product and have health concerns.
Contact Pendopharm Division of Pharmascience Inc. by calling 1-888-550-6060 or emailing [email protected] if you have questions about this recall.
Tilray Brands, Inc. ("Tilray Brands" or the "Company") , a leading global lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced today that it has filed a prospectus...
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown Magnificent Mile on June 21?22, 2024. This biennial...
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF1, used...
The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule...
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)- Data to be presented from...
We are advised by OsteoStrong that journalists and other readers should disregard the news release, OsteoStrong Celebrates Success and Innovation at 11th Annual Global Franchise Owner Convention, issued May 9, 2024 over PR Newswire.
SOURCE...